Rationale for targeting immune checkpoints in diseases

Other programmes of interest

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

I agree that this educational programme:

Programme summary

Supporter Acknowledgement

I agree that this educational programme:

Brought to you by

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.

Other programmes of interest

Episode

3

of 3

How are new data shaping the landscape in HER2-mutant NSCLC?

Experts

Endorsed by

Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Experts

Rationale for targeting immune checkpoints in diseases

Publication Date

I agree that this educational programme:

Programme summary

Share this programme

Supporter Acknowledgement

I agree that this educational programme:

Brought to you by

GI CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from Bayer, Ipsen, BeiGene Europe, Pierre Fabre Laboratories, Amgen and AstraZeneca US.

Other programmes of interest

Real-world outcomes of elacestrant in ER+/HER2−, ESR1-mutant metastatic breast cancer

Experts

Optimising outcomes in multiple myeloma

Experts

ROS1-positive NSCLC

Experts

Endorsed by

Exploring pan-RAS targeting beyond G12C in non-small cell lung cancer (NSCLC)

Experts

Endorsed by

Episode

3

of 3

How are new data shaping the landscape in HER2-mutant NSCLC?

Experts

Endorsed by

Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Experts